Inspire Medical Systems (INSP) Financials

$143.24 -2.71 (-1.86%)

Closing price 05/23/2025 03:59 PM Eastern

Extended Trading

$143.20 -0.04 (-0.03%)

As of 05/23/2025 07:45 PM Eastern

Annual Income Statements for Inspire Medical Systems

This table shows Inspire Medical Systems' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016
Net Income / (Loss) Attributable to Common Shareholders	54	-21	-45	-42	-57	-33	-22	-18	-19
Consolidated Net Income / (Loss)	54	-21	-45	-42	-57	-33	-22	-18	-19
Net Income / (Loss) Continuing Operations	54	-21	-45	-42	-57	-33	-22	-18	-19
Total Pre-Tax Income	58	-20	-44	-42	-57	-33	-22	-18	-19
Total Operating Income	36	-40	-48	-40	-56	-35	-20	-16	-17
Total Gross Profit	680	528	342	200	98	68	41	23	13
Total Revenue	803	625	408	233	115	82	51	29	16
Operating Revenue	803	625	408	233	115	82	51	29	16
Total Cost of Revenue	123	97	66	33	18	14	10	6.02	3.91
Total Operating Expenses	644	568	389	240	154	103	61	39	30
Selling, General & Admin Expense	530	452	321	203	128	90	54	32	23
Research & Development Expense	114	117	69	37	26	13	7.39	6.19	7.09
Total Other Income / (Expense), net	22	20	3.32	-2.12	-0.88	1.69	-1.45	-1.51	-1.28
Interest & Investment Income	23	21	5.05	0.13	1.09	3.80	1.87	0.20	0.06
Other Income / (Expense), net	-0.86	-0.20	-0.05	-0.12	0.15	0.01	-0.02	0.04	-0.03
Income Tax Expense	4.94	1.25	0.61	0.07	0.12	0.04	0.00	0.00	0.00
Basic Earnings per Share	$1.80	($0.72)	($1.60)	($1.54)	($2.19)	($1.40)	($1.50)	($14.88)	($16.90)
Weighted Average Basic Shares Outstanding	29.76M	29.30M	28.07M	27.26M	26.07M	23.80M	14.58M	1.18M	1.10M
Diluted Earnings per Share	$1.75	($0.72)	($1.60)	($1.54)	($2.19)	($1.40)	($1.50)	($14.88)	($16.90)
Weighted Average Diluted Shares Outstanding	30.54M	29.30M	28.07M	27.26M	26.07M	23.80M	14.58M	1.18M	1.10M
Weighted Average Basic & Diluted Shares Outstanding	29.67M	29.59M	29.05M	27.53M	26.07M	23.80M	14.58M	1.18M	1.10M

This table shows Inspire Medical Systems' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	2.99	35	18	9.79	-10	15	-8.54	-12	-15	3.15	-17
Consolidated Net Income / (Loss)	2.99	35	18	9.79	-10	15	-8.54	-12	-15	3.15	-17
Net Income / (Loss) Continuing Operations	2.99	35	18	9.79	-10	15	-8.54	-12	-15	3.15	-17
Total Pre-Tax Income	4.16	37	20	11	-9.36	15	-8.20	-12	-15	3.28	-17
Total Operating Income	-1.49	32	14	5.10	-15	9.30	-13	-17	-19	-0.34	-17
Total Gross Profit	171	204	171	166	139	164	129	127	108	116	89
Total Revenue	201	240	203	196	164	193	153	151	128	138	109
Operating Revenue	201	240	203	196	164	193	153	151	128	138	109
Total Cost of Revenue	31	36	32	30	25	28	24	24	20	22	20
Total Operating Expenses	172	172	156	161	154	155	142	143	128	116	107
Selling, General & Admin Expense	144	142	130	132	126	124	113	113	102	95	86
Research & Development Expense	28	30	26	29	29	31	29	31	26	21	21
Total Other Income / (Expense), net	5.64	4.75	6.01	5.75	5.86	5.94	5.27	4.86	4.29	3.61	0.59
Interest & Investment Income	5.07	5.55	5.89	5.88	5.92	5.87	5.50	4.92	4.27	3.37	1.35
Other Income / (Expense), net	0.58	-0.78	0.12	-0.14	-0.06	0.07	-0.22	-0.06	0.02	0.24	-0.10
Income Tax Expense	1.17	1.41	1.83	1.05	0.65	0.48	0.34	0.21	0.22	0.13	0.25
Basic Earnings per Share	$0.10	$1.19	$0.62	$0.33	($0.34)	$0.51	($0.29)	($0.41)	($0.53)	$0.14	($0.60)
Weighted Average Basic Shares Outstanding	29.70M	29.76M	29.88M	29.73M	29.62M	29.30M	29.37M	29.23M	29.09M	28.07M	28.23M
Diluted Earnings per Share	$0.10	$1.17	$0.60	$0.32	($0.34)	$0.51	($0.29)	($0.41)	($0.53)	$0.14	($0.60)
Weighted Average Diluted Shares Outstanding	30.31M	30.54M	30.63M	30.41M	29.62M	29.30M	29.37M	29.23M	29.09M	28.07M	28.23M
Weighted Average Basic & Diluted Shares Outstanding	29.49M	29.67M	29.97M	29.82M	29.71M	29.59M	29.52M	29.34M	29.17M	29.05M	28.89M

This table details how cash moves in and out of Inspire Medical Systems' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016
Net Change in Cash & Equivalents	-35	-256	227	24	168	-74	88	2.27	-5.44
Net Cash From Operating Activities	130	25	12	-20	-53	-33	-19	-16	-18
Net Cash From Continuing Operating Activities	130	25	12	-20	-53	-33	-19	-16	-18
Net Income / (Loss) Continuing Operations	54	-21	-45	-42	-57	-33	-22	-18	-19
Consolidated Net Income / (Loss)	54	-21	-45	-42	-57	-33	-22	-18	-19
Depreciation Expense	6.55	2.85	1.86	1.22	0.84	0.50	0.39	0.29	0.10
Amortization Expense	-8.86	-2.47	-0.00	0.01	-	-0.72	-0.08	0.32	0.18
Non-Cash Adjustments To Reconcile Net Income	117	86	53	28	14	7.19	1.96	0.34	0.05
Changes in Operating Assets and Liabilities, net	-38	-41	1.81	-6.86	-11	-6.57	0.86	0.78	0.24
Net Cash From Investing Activities	-113	-295	-20	29	87	-44	-83	-7.60	-0.31
Net Cash From Continuing Investing Activities	-113	-295	-20	29	87	-44	-83	-7.60	-0.31
Purchase of Property, Plant & Equipment	-39	-24	-9.10	-4.67	-2.46	-2.74	-0.25	-0.41	-0.31
Purchase of Investments	-419	-281	-11	-9.99	-53	-178	-115	-8.97	0.00
Sale and/or Maturity of Investments	345	10	0.00	44	142	137	32	1.78	0.00
Net Cash From Financing Activities	-52	14	235	15	134	1.96	190	26	13
Net Cash From Continuing Financing Activities	-52	14	235	15	134	1.96	190	26	13
Repayment of Debt	0.00	0.00	-25	0.00	0.00	-0.53	0.00	0.00	-
Repurchase of Common Equity	-75	0.00	0.00	-	-	-	-	-	-
Issuance of Common Equity	5.61	5.30	248	3.47	127	1.36	182	0.00	0.00
Other Financing Activities, net	17	8.65	12	11	7.05	1.14	0.56	0.24	0.47
Effect of Exchange Rate Changes	-0.12	0.16	0.08	-0.02	0.01	0.01	0.03	0.00	0.00
Cash Interest Paid	0.02	0.00	2.32	1.89	1.89	2.03	2.02	1.32	1.23

This table details how cash moves in and out of Inspire Medical Systems' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-96	2.64	-41	13	-10	-144	-137	25	0.54	24	231
Net Cash From Operating Activities	-6.70	69	52	-0.08	8.86	17	3.64	5.09	-1.34	19	11
Net Cash From Continuing Operating Activities	-6.70	69	52	-0.08	8.86	17	3.64	5.09	-1.34	19	11
Net Income / (Loss) Continuing Operations	2.99	35	18	9.79	-10	15	-8.54	-12	-15	3.15	-17
Consolidated Net Income / (Loss)	2.99	35	18	9.79	-10	15	-8.54	-12	-15	3.15	-17
Depreciation Expense	3.04	2.48	1.85	1.38	0.84	0.82	0.78	0.66	0.59	0.57	0.51
Amortization Expense	-1.21	-1.54	-2.41	-2.44	-2.47	-2.40	-0.07	-	-0.00	-	-
Non-Cash Adjustments To Reconcile Net Income	32	30	29	33	25	24	21	23	19	15	14
Changes in Operating Assets and Liabilities, net	-43	3.11	5.68	-42	-4.95	-20	-9.30	-6.48	-5.09	0.20	13
Net Cash From Investing Activities	-1.55	3.76	-103	5.62	-20	-152	-144	4.90	-3.75	-2.95	-3.76
Net Cash From Continuing Investing Activities	-1.55	3.76	-103	5.62	-20	-152	-144	4.90	-3.75	-2.95	-3.76
Purchase of Property, Plant & Equipment	-8.41	-7.03	-8.01	-12	-12	-8.03	-6.99	-4.86	-3.75	-2.95	-3.51
Purchase of Investments	-17	-81	-226	-56	-56	-144	-137	-0.25	0.00	-	-0.25
Sale and/or Maturity of Investments	24	92	131	74	48	0.25	-	10	0.00	-	-
Net Cash From Financing Activities	-88	-70	9.89	7.09	0.77	-10	3.50	15	5.63	7.29	224
Net Cash From Continuing Financing Activities	-88	-70	9.89	7.09	0.77	-10	3.50	15	5.63	7.29	224
Repurchase of Common Equity	-75	-	-	-	-	-	-	-	-	-	-
Other Financing Activities, net	-13	2.69	9.89	3.66	0.77	-13	3.50	12	5.63	5.69	1.76
Effect of Exchange Rate Changes	-0.25	-0.17	0.27	-0.01	-0.21	0.21	-0.05	-0.00	0.01	0.18	-0.13

This table presents Inspire Medical Systems' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017
Total Assets	808	677	565	295	281	181	200	25
Total Current Assets	631	594	530	269	270	171	199	24
Cash & Equivalents	150	186	442	214	191	23	97	8.96
Short-Term Investments	295	275	9.82	0.00	44	127	91	7.19
Accounts Receivable	93	90	61	34	25	13	6.67	3.86
Inventories, net	80	34	12	17	8.48	5.83	2.67	3.67
Prepaid Expenses	12	9.60	5.51	2.66	1.97	2.21	1.73	0.43
Plant, Property, & Equipment, net	72	40	17	8.49	5.31	3.05	0.80	0.99
Total Noncurrent Assets	106	43	18	18	6.01	7.57	0.00	0.00
Long-Term Investments	71	9.14	0.00	9.94	0.00	6.28	0.00	-
Other Noncurrent Operating Assets	35	34	18	8.12	6.01	1.30	0.00	-
Total Liabilities & Shareholders' Equity	808	677	565	295	281	181	200	25
Total Liabilities	119	104	69	66	51	41	36	24
Total Current Liabilities	89	78	61	41	21	17	11	7.15
Accounts Payable	39	39	27	12	7.21	4.46	3.43	3.00
Accrued Expenses	50	39	34	20	14	12	7.73	4.15
Total Noncurrent Liabilities	30	26	7.68	25	31	25	25	17
Other Noncurrent Operating Liabilities	30	26	7.68	8.93	5.97	0.04	0.00	0.16
Commitments & Contingencies	0.00	0.00	-	-	-	-	-	-
Total Equity & Noncontrolling Interests	690	573	496	229	230	140	164	1.33
Total Preferred & Common Equity	690	573	496	229	230	140	164	1.33
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	-	119
Total Common Equity	690	573	496	229	230	140	164	-118
Common Stock	981	917	820	508	467	320	311	7.31
Retained Earnings	-292	-345	-324	-279	-237	-180	-147	-125
Accumulated Other Comprehensive Income / (Loss)	0.54	0.80	-0.09	-0.06	0.03	0.10	-0.05	0.00

This table presents Inspire Medical Systems' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	731	796	728	686	639	618	572	528
Total Current Assets	572	583	607	572	570	560	534	496
Cash & Equivalents	54	148	188	175	330	467	442	418
Short-Term Investments	315	263	252	266	134	0.00	9.93	9.74
Accounts Receivable	93	90	80	72	71	64	60	48
Inventories, net	100	67	59	49	26	21	16	15
Prepaid Expenses	10	14	29	9.55	7.80	8.69	6.09	4.35
Plant, Property, & Equipment, net	77	67	62	52	32	25	21	14
Total Noncurrent Assets	82	146	60	61	38	33	17	18
Long-Term Investments	45	113	26	28	2.96	-	-	0.00
Other Noncurrent Operating Assets	37	33	33	34	35	33	17	18
Total Liabilities & Shareholders' Equity	731	796	728	686	639	618	572	528
Total Liabilities	95	100	90	97	95	89	67	57
Total Current Liabilities	63	74	66	72	70	67	60	49
Accounts Payable	29	35	34	44	40	40	36	20
Accrued Expenses	34	39	32	28	30	27	23	29
Total Noncurrent Liabilities	32	25	25	25	25	22	7.33	8.03
Other Noncurrent Operating Liabilities	32	25	25	25	25	22	7.33	8.03
Total Equity & Noncontrolling Interests	636	697	638	589	544	529	505	470
Total Preferred & Common Equity	636	697	638	589	544	529	505	470
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	636	697	638	589	544	529	505	470
Common Stock	924	1,022	984	944	904	881	844	798
Retained Earnings	-289	-327	-346	-355	-360	-352	-340	-327
Accumulated Other Comprehensive Income / (Loss)	0.23	1.70	-0.12	0.12	0.04	0.10	0.03	-0.36

This table displays calculated financial ratios and metrics derived from Inspire Medical Systems' official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016
Growth Metrics	-	-	-	-	-	-	-	-	-
Revenue Growth	28.49%	53.19%	74.75%	102.28%	40.62%	62.18%	77.10%	73.90%	0.00%
EBITDA Growth	182.11%	12.44%	-18.21%	29.86%	-57.31%	-74.82%	-30.73%	9.64%	0.00%
EBIT Growth	187.06%	15.06%	-19.20%	28.71%	-60.71%	-71.06%	-27.77%	7.64%	0.00%
NOPAT Growth	217.17%	15.38%	-19.43%	29.10%	-61.07%	-71.25%	-27.34%	7.25%	0.00%
Net Income Growth	352.96%	52.87%	-6.75%	26.50%	-72.08%	-52.30%	-24.65%	5.49%	0.00%
EPS Growth	343.06%	55.00%	-3.90%	29.68%	-56.43%	6.67%	89.92%	11.95%	0.00%
Operating Cash Flow Growth	428.32%	113.10%	157.50%	62.07%	-61.50%	-75.70%	-18.38%	12.02%	0.00%
Free Cash Flow Firm Growth	57.12%	-79.35%	-29.11%	26.48%	-57.32%	-142.43%	-3.81%	0.00%	0.00%
Invested Capital Growth	68.12%	130.96%	50.51%	47.19%	133.65%	1,105.04%	-56.51%	0.00%	0.00%
Revenue Q/Q Growth	6.25%	9.58%	17.08%	16.11%	19.84%	14.43%	15.01%	0.00%	0.00%
EBITDA Q/Q Growth	279.95%	15.30%	4.14%	11.95%	4.11%	-12.41%	-9.43%	0.00%	0.00%
EBIT Q/Q Growth	161.10%	18.95%	3.55%	11.42%	3.92%	-14.34%	-5.72%	0.00%	0.00%
NOPAT Q/Q Growth	174.44%	19.30%	3.03%	11.62%	3.82%	-14.41%	-5.44%	0.00%	0.00%
Net Income Q/Q Growth	61.91%	35.44%	10.99%	10.81%	2.71%	-14.86%	-2.47%	0.00%	0.00%
EPS Q/Q Growth	60.55%	33.95%	12.09%	9.94%	6.01%	-143.89%	83.55%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	66.27%	-7.51%	266.08%	19.40%	3.57%	-11.88%	3.55%	0.00%	0.00%
Free Cash Flow Firm Q/Q Growth	55.33%	-24.98%	7.10%	1.88%	-0.74%	-18.07%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	0.58%	33.75%	4.55%	18.33%	8.85%	-3.34%	-75.20%	0.00%	0.00%
Profitability Metrics	-	-	-	-	-	-	-	-	-
Gross Margin	84.68%	84.54%	83.79%	85.74%	84.73%	83.37%	80.12%	78.93%	76.23%
EBITDA Margin	4.10%	-6.42%	-11.23%	-16.60%	-47.86%	-42.78%	-39.69%	-53.77%	-103.48%
Operating Margin	4.49%	-6.45%	-11.67%	-17.07%	-48.72%	-42.53%	-40.28%	-56.02%	-105.03%
EBIT Margin	4.39%	-6.48%	-11.68%	-17.12%	-48.59%	-42.52%	-40.31%	-55.87%	-105.20%
Profit (Net Income) Margin	6.67%	-3.39%	-11.00%	-18.01%	-49.58%	-40.52%	-43.14%	-61.30%	-112.79%
Tax Burden Percent	91.54%	106.26%	101.38%	100.17%	100.20%	100.12%	100.00%	100.00%	100.00%
Interest Burden Percent	165.93%	49.19%	92.92%	105.01%	101.83%	95.18%	107.03%	109.71%	107.21%
Effective Tax Rate	8.46%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	23.92%	-38.20%	-89.77%	-112.12%	-273.74%	-523.59%	-1,209.38%	-1,362.79%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	19.77%	-39.73%	-86.21%	-105.20%	-263.26%	-517.60%	-1,200.09%	-5,343.16%	0.00%
Return on Net Nonoperating Assets (RNNOA)	-15.44%	34.24%	77.39%	93.79%	242.78%	501.70%	1,182.97%	-1,276.40%	0.00%
Return on Equity (ROE)	8.48%	-3.96%	-12.38%	-18.33%	-30.96%	-21.88%	-26.41%	-2,639.19%	0.00%
Cash Return on Invested Capital (CROIC)	-26.89%	-117.34%	-130.09%	-150.29%	-353.85%	-692.94%	-1,130.61%	-1,562.79%	0.00%
Operating Return on Assets (OROA)	4.74%	-6.52%	-11.08%	-13.87%	-24.25%	-18.30%	-18.11%	-63.61%	0.00%
Return on Assets (ROA)	7.21%	-3.41%	-10.44%	-14.59%	-24.74%	-17.44%	-19.39%	-69.79%	0.00%
Return on Common Equity (ROCE)	8.48%	-3.96%	-12.38%	-18.33%	-30.96%	-21.88%	-7.38%	234,243.18%	0.00%
Return on Equity Simple (ROE_SIMPLE)	7.76%	-3.69%	-9.05%	-18.36%	-24.90%	-23.77%	-13.31%	-1,319.59%	0.00%
Net Operating Profit after Tax (NOPAT)	33	-28	-33	-28	-39	-24	-14	-11	-12
NOPAT Margin	4.11%	-4.51%	-8.17%	-11.95%	-34.10%	-29.77%	-28.19%	-39.21%	-73.52%
Net Nonoperating Expense Percent (NNEP)	4.15%	1.53%	-3.55%	-6.92%	-10.48%	-5.99%	-9.28%	3,980.38%	0.00%
Return On Investment Capital (ROIC_SIMPLE)	4.79%	-4.92%	-6.72%	-	-	-	-	-	-
Cost of Revenue to Revenue	15.32%	15.46%	16.21%	14.26%	15.27%	16.63%	19.88%	21.07%	23.77%
SG&A Expenses to Revenue	65.97%	72.34%	78.63%	86.81%	110.83%	110.26%	105.80%	113.27%	138.09%
R&D to Revenue	14.22%	18.65%	16.83%	16.00%	22.61%	15.65%	14.60%	21.68%	43.17%
Operating Expenses to Revenue	80.19%	90.99%	95.46%	102.82%	133.44%	125.90%	120.40%	134.95%	181.26%
Earnings before Interest and Taxes (EBIT)	35	-40	-48	-40	-56	-35	-20	-16	-17
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	33	-40	-46	-39	-55	-35	-20	-15	-17
Valuation Ratios	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	8.05	10.49	14.67	27.48	22.05	12.77	5.51	0.00	0.00
Price to Tangible Book Value (P/TBV)	8.05	10.49	14.67	27.48	22.05	12.77	5.51	0.00	0.00
Price to Revenue (P/Rev)	6.92	9.61	17.84	26.97	43.91	21.76	17.87	3.78	6.57
Price to Earnings (P/E)	103.82	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.96%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	29.10	53.76	153.07	205.69	241.25	192.02	1,036.20	138.34	0.00
Enterprise Value to Revenue (EV/Rev)	6.28	8.86	16.74	26.11	42.09	20.16	14.64	7.96	0.00
Enterprise Value to EBITDA (EV/EBITDA)	153.06	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	143.03	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	152.55	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	38.69	224.58	590.03	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.11	0.11	0.18	0.15	12.40	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.07	0.11	0.18	0.15	12.40	0.00
Financial Leverage	-0.78	-0.86	-0.90	-0.89	-0.92	-0.97	-0.99	0.24	0.00
Leverage Ratio	1.18	1.16	1.19	1.26	1.25	1.26	1.36	18.91	0.00
Compound Leverage Factor	1.95	0.57	1.10	1.32	1.27	1.19	1.46	20.74	0.00
Debt to Total Capital	0.00%	0.00%	0.00%	9.84%	9.72%	14.92%	13.19%	92.54%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	3.62%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	6.22%	9.72%	14.92%	13.19%	92.54%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	669.62%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	90.16%	90.28%	85.08%	86.81%	-662.16%	0.00%
Debt to EBITDA	0.00	0.00	0.00	-0.65	-0.45	-0.70	-1.24	-1.07	0.00
Net Debt to EBITDA	0.00	0.00	0.00	5.15	3.80	3.74	8.13	-0.02	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	-0.41	-0.45	-0.70	-1.24	-1.07	0.00
Debt to NOPAT	0.00	0.00	0.00	-0.90	-0.63	-1.00	-1.75	-1.47	0.00
Net Debt to NOPAT	0.00	0.00	0.00	7.15	5.33	5.37	11.45	-0.03	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	-0.57	-0.63	-1.00	-1.75	-1.47	0.00
Altman Z-Score	29.52	35.48	64.04	57.13	58.72	25.31	15.05	-4.40	0.00
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	72.04%	8,975.58%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-
Current Ratio	7.13	7.60	8.66	6.50	13.02	10.12	17.86	3.37	0.00
Quick Ratio	6.09	7.05	8.38	6.02	12.52	9.65	17.47	2.80	0.00
Cash Flow Metrics	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-37	-87	-48	-37	-51	-32	-13	-13	0.00
Operating Cash Flow to CapEx	332.91%	104.33%	127.19%	-431.00%	-2,160.69%	-1,199.20%	-7,477.60%	-3,832.77%	-5,865.69%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	-28.79	-17.57	-24.02	-15.26	-4.04	-7.33	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	6.90	-9.45	-25.06	-15.50	-5.66	-9.01	-13.78
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	1.47	-11.65	-26.22	-16.79	-5.73	-9.24	-14.01
Efficiency Ratios	-	-	-	-	-	-	-	-	-
Asset Turnover	1.08	1.01	0.95	0.81	0.50	0.43	0.45	1.14	0.00
Accounts Receivable Turnover	8.78	8.27	8.55	7.88	6.04	8.29	9.61	7.40	0.00
Inventory Turnover	2.16	4.22	4.54	2.59	2.46	3.21	3.17	1.64	0.00
Fixed Asset Turnover	14.35	21.83	31.70	33.83	27.62	42.66	56.34	28.74	0.00
Accounts Payable Turnover	3.17	2.94	3.43	3.53	3.02	3.46	3.13	2.01	0.00
Days Sales Outstanding (DSO)	41.59	44.14	42.69	46.32	60.41	44.04	37.97	49.29	0.00
Days Inventory Outstanding (DIO)	169.17	86.49	80.37	140.99	148.22	113.72	115.01	222.59	0.00
Days Payable Outstanding (DPO)	115.04	124.13	106.31	103.50	120.83	105.52	116.64	181.83	0.00
Cash Conversion Cycle (CCC)	95.72	6.51	16.76	83.81	87.80	52.24	36.33	90.05	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-
Invested Capital	173	103	45	30	20	8.62	0.72	1.64	0.00
Invested Capital Turnover	5.81	8.47	10.99	9.38	8.03	17.59	42.89	34.75	0.00
Increase / (Decrease) in Invested Capital	70	58	15	9.50	12	7.90	-0.93	1.64	0.00
Enterprise Value (EV)	5,039	5,537	6,826	6,095	4,857	1,654	741	227	0.00
Market Capitalization	5,555	6,006	7,277	6,294	5,066	1,786	904	108	108
Book Value per Share	$23.02	$19.39	$17.17	$8.37	$8.53	$5.81	$7.66	($100.10)	$0.00
Tangible Book Value per Share	$23.02	$19.39	$17.17	$8.37	$8.53	$5.81	$7.66	($100.10)	$0.00
Total Capital	690	573	496	254	254	164	189	18	0.00
Total Debt	0.00	0.00	0.00	25	25	25	25	16	0.00
Total Long-Term Debt	0.00	0.00	0.00	16	25	25	25	16	0.00
Net Debt	-517	-470	-451	-199	-210	-131	-163	0.32	0.00
Capital Expenditures (CapEx)	39	24	9.10	4.67	2.46	2.74	0.25	0.41	0.31
Debt-free, Cash-free Net Working Capital (DFCFNWC)	97	55	17	22	15	4.32	-0.09	0.81	0.00
Debt-free Net Working Capital (DFNWC)	542	516	469	236	249	154	188	17	0.00
Net Working Capital (NWC)	542	516	469	227	249	154	188	17	0.00
Net Nonoperating Expense (NNE)	-20	-7.04	12	14	18	8.82	7.56	6.31	6.45
Net Nonoperating Obligations (NNO)	-517	-470	-451	-199	-210	-131	-163	0.32	0.00
Total Depreciation and Amortization (D&A)	-2.31	0.38	1.85	1.23	0.84	-0.22	0.31	0.60	0.28
Debt-free, Cash-free Net Working Capital to Revenue	12.05%	8.84%	4.27%	9.41%	12.81%	5.26%	-0.17%	2.82%	0.00%
Debt-free Net Working Capital to Revenue	67.55%	82.53%	114.95%	101.30%	215.93%	187.42%	371.84%	59.33%	0.00%
Net Working Capital to Revenue	67.55%	82.53%	114.95%	97.36%	215.93%	187.42%	371.84%	59.33%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$1.80	($0.72)	($1.60)	($1.54)	($2.19)	($1.40)	($1.50)	$0.00	$0.00
Adjusted Weighted Average Basic Shares Outstanding	29.76M	29.30M	28.07M	27.26M	27.13M	24.13M	23.44M	0.00	0.00
Adjusted Diluted Earnings per Share	$1.75	($0.72)	($1.60)	($1.54)	($2.19)	($1.40)	($1.50)	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	30.54M	29.30M	28.07M	27.26M	27.13M	24.13M	23.44M	0.00	0.00
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	($2.19)	($1.40)	($1.50)	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	29.67M	29.59M	29.05M	27.53M	26.07M	23.80M	14.58M	0.00	0.00
Normalized Net Operating Profit after Tax (NOPAT)	33	-28	-33	-28	-39	-24	-14	-11	-12
Normalized NOPAT Margin	4.11%	-4.51%	-8.17%	-11.95%	-34.10%	-29.77%	-28.19%	-39.21%	-73.52%
Pre Tax Income Margin	7.28%	-3.19%	-10.85%	-17.98%	-49.48%	-40.47%	-43.14%	-61.30%	-112.79%
Debt Service Ratios	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	-28.41	-18.78	-26.48	-16.46	-6.17	-9.11	-13.26
NOPAT to Interest Expense	0.00	0.00	-19.87	-13.11	-18.59	-11.53	-4.32	-6.39	-9.27
EBIT Less CapEx to Interest Expense	0.00	0.00	-33.83	-20.98	-27.64	-17.76	-6.25	-9.34	-13.50
NOPAT Less CapEx to Interest Expense	0.00	0.00	-25.29	-15.30	-19.75	-12.82	-4.39	-6.63	-9.50
Payout Ratios	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	140.16%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Inspire Medical Systems' official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	22.75%	24.52%	32.54%	29.65%	28.24%	39.60%	40.40%	65.33%	84.34%	75.90%	77.01%
EBITDA Growth	105.49%	311.48%	206.85%	124.43%	10.49%	1,539.37%	22.62%	-16.51%	-19.99%	131.58%	-76.78%
EBIT Growth	94.06%	231.97%	205.41%	129.80%	21.57%	10,068.09%	20.82%	-17.73%	-20.99%	94.91%	-75.96%
NOPAT Growth	89.97%	240.39%	238.18%	139.62%	21.95%	2,895.04%	21.65%	-18.51%	-21.44%	74.72%	-75.52%
Net Income Growth	129.91%	138.60%	316.59%	181.94%	35.13%	368.67%	49.31%	17.52%	7.61%	231.74%	-62.82%
EPS Growth	129.41%	129.41%	306.90%	178.05%	35.85%	264.29%	51.67%	22.64%	13.11%	275.00%	-57.89%
Operating Cash Flow Growth	-175.65%	300.65%	1,337.14%	-101.53%	759.23%	-10.39%	-66.93%	185.52%	89.46%	2,525.20%	3,355.03%
Free Cash Flow Firm Growth	-32.09%	20.03%	-87.57%	-395.52%	-166.66%	-223.11%	-47.65%	40.31%	-9.57%	-41.89%	-121.22%
Invested Capital Growth	84.99%	68.12%	123.56%	176.15%	127.92%	130.96%	80.53%	18.22%	42.07%	50.51%	70.35%
Revenue Q/Q Growth	-16.02%	17.98%	3.73%	19.43%	-14.80%	25.57%	1.46%	18.14%	-7.25%	26.30%	19.48%
EBITDA Q/Q Growth	-97.10%	130.92%	254.98%	123.12%	-265.98%	159.96%	18.84%	15.29%	-4,076.63%	102.83%	-22.19%
EBIT Q/Q Growth	-102.92%	115.48%	190.81%	132.49%	-263.05%	168.42%	17.80%	14.48%	-20,624.47%	99.46%	-22.22%
NOPAT Q/Q Growth	-103.48%	135.27%	183.01%	143.22%	-218.28%	195.51%	18.84%	14.87%	-4,135.88%	97.32%	-22.75%
Net Income Q/Q Growth	-91.51%	90.43%	88.88%	197.88%	-167.77%	272.87%	28.55%	22.51%	-589.65%	118.70%	-16.27%
EPS Q/Q Growth	-91.45%	95.00%	87.50%	194.12%	-166.67%	275.86%	29.27%	22.64%	-478.57%	123.33%	-13.21%
Operating Cash Flow Q/Q Growth	-109.69%	32.32%	67,129.49%	-100.88%	-48.69%	374.63%	-28.55%	478.87%	-106.97%	75.14%	284.78%
Free Cash Flow Firm Q/Q Growth	-160.57%	51.89%	21.91%	-34.94%	-57.76%	-12.83%	-106.31%	27.38%	-91.15%	48.44%	16.59%
Invested Capital Q/Q Growth	28.05%	0.58%	0.05%	43.55%	16.37%	33.75%	23.59%	18.48%	17.93%	4.55%	-19.07%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	84.75%	84.99%	84.06%	84.77%	84.91%	85.43%	84.10%	83.95%	84.45%	83.94%	81.88%
EBITDA Margin	0.46%	13.37%	6.83%	2.00%	-10.31%	4.05%	-8.47%	-10.59%	-14.77%	0.34%	-15.37%
Operating Margin	-0.74%	13.30%	7.05%	2.60%	-9.28%	4.83%	-8.79%	-10.99%	-15.25%	-0.24%	-15.75%
EBIT Margin	-0.45%	12.98%	7.10%	2.53%	-9.32%	4.87%	-8.93%	-11.03%	-15.23%	-0.07%	-15.84%
Profit (Net Income) Margin	1.49%	14.69%	9.10%	5.00%	-6.10%	7.67%	-5.57%	-7.91%	-12.06%	2.28%	-15.43%
Tax Burden Percent	71.94%	96.15%	91.00%	90.29%	106.95%	96.87%	104.15%	101.82%	101.42%	96.18%	101.48%
Interest Burden Percent	-458.54%	117.78%	140.80%	218.49%	61.23%	162.65%	59.88%	70.46%	78.07%	-3,484.04%	95.99%
Effective Tax Rate	28.06%	3.85%	9.00%	9.71%	0.00%	3.13%	0.00%	0.00%	0.00%	3.82%	0.00%
Return on Invested Capital (ROIC)	-2.61%	74.35%	38.89%	14.15%	-49.79%	39.61%	-58.62%	-70.35%	-111.09%	-2.57%	-113.45%
ROIC Less NNEP Spread (ROIC-NNEP)	-3.53%	73.43%	37.79%	13.04%	-49.93%	38.36%	-58.82%	-70.25%	-110.53%	-3.63%	-111.90%
Return on Net Nonoperating Assets (RNNOA)	2.55%	-57.36%	-30.20%	-10.42%	42.05%	-33.06%	51.88%	59.56%	96.96%	3.26%	100.93%
Return on Equity (ROE)	-0.07%	16.99%	8.69%	3.73%	-7.73%	6.55%	-6.74%	-10.79%	-14.13%	0.69%	-12.52%
Cash Return on Invested Capital (CROIC)	-32.69%	-26.89%	-66.71%	-102.25%	-107.24%	-117.34%	-115.80%	-81.97%	-114.50%	-130.09%	-153.54%
Operating Return on Assets (OROA)	-0.53%	14.03%	7.48%	2.66%	-9.79%	4.90%	-8.73%	-12.75%	-16.49%	-0.06%	-13.68%
Return on Assets (ROA)	1.76%	15.89%	9.58%	5.24%	-6.41%	7.72%	-5.44%	-9.14%	-13.06%	2.17%	-13.33%
Return on Common Equity (ROCE)	-0.07%	16.99%	8.69%	3.73%	-7.73%	6.55%	-6.74%	-10.79%	-14.13%	0.69%	-12.52%
Return on Equity Simple (ROE_SIMPLE)	10.46%	0.00%	4.74%	0.94%	-2.67%	0.00%	-6.02%	-7.76%	-8.64%	0.00%	-10.72%
Net Operating Profit after Tax (NOPAT)	-1.07	31	13	4.60	-11	9.01	-9.43	-12	-14	-0.32	-12
NOPAT Margin	-0.53%	12.79%	6.41%	2.35%	-6.50%	4.68%	-6.15%	-7.69%	-10.67%	-0.23%	-11.02%
Net Nonoperating Expense Percent (NNEP)	0.92%	0.93%	1.10%	1.11%	0.14%	1.25%	0.20%	-0.10%	-0.55%	1.07%	-1.55%
Return On Investment Capital (ROIC_SIMPLE)	-0.17%	4.44%	-	-	-	1.57%	-	-	-	-0.07%	-
Cost of Revenue to Revenue	15.25%	15.01%	15.94%	15.24%	15.09%	14.57%	15.90%	16.05%	15.55%	16.06%	18.12%
SG&A Expenses to Revenue	71.67%	59.03%	64.17%	67.43%	76.59%	64.47%	73.87%	74.54%	79.74%	68.77%	78.40%
R&D to Revenue	13.81%	12.65%	12.84%	14.73%	17.59%	16.13%	19.01%	20.40%	19.95%	15.41%	19.23%
Operating Expenses to Revenue	85.48%	71.69%	77.01%	82.16%	94.18%	80.60%	92.88%	94.93%	99.70%	84.18%	97.63%
Earnings before Interest and Taxes (EBIT)	-0.91	31	14	4.96	-15	9.37	-14	-17	-19	-0.09	-17
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	0.93	32	14	3.91	-17	7.79	-13	-16	-19	0.48	-17
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	7.43	8.05	9.04	6.23	10.77	10.49	10.70	17.89	13.47	14.67	10.43
Price to Tangible Book Value (P/TBV)	7.43	8.05	9.04	6.23	10.77	10.49	10.70	17.89	13.47	14.67	10.43
Price to Revenue (P/Rev)	5.63	6.92	8.33	5.63	9.60	9.61	10.21	18.00	14.58	17.84	14.07
Price to Earnings (P/E)	71.06	103.82	190.45	661.49	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	1.41%	0.96%	0.53%	0.15%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	19.45	29.10	33.51	20.40	48.99	53.76	69.53	144.50	120.70	153.07	104.90
Enterprise Value to Revenue (EV/Rev)	5.13	6.28	7.64	4.97	8.89	8.86	9.39	17.11	13.61	16.74	12.85
Enterprise Value to EBITDA (EV/EBITDA)	84.95	153.06	665.91	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	86.93	143.03	427.62	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	93.66	152.55	479.35	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	37.60	38.69	73.65	118.24	168.47	224.58	200.87	264.66	276.29	590.03	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.72	-0.78	-0.80	-0.80	-0.84	-0.86	-0.88	-0.85	-0.88	-0.90	-0.90
Leverage Ratio	1.16	1.18	1.16	1.15	1.15	1.16	1.15	1.20	1.18	1.19	1.17
Compound Leverage Factor	-5.30	1.39	1.63	2.52	0.70	1.89	0.69	0.85	0.92	-41.32	1.12
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	31.25	29.50	39.10	27.63	40.34	35.72	37.62	64.85	61.58	64.32	52.01
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	9.01	7.13	7.84	9.25	7.93	7.60	8.14	8.40	8.91	8.66	10.05
Quick Ratio	7.28	6.09	6.74	7.91	7.12	7.05	7.65	7.96	8.55	8.38	9.66
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-103	-40	-82	-105	-78	-49	-44	-21	-29	-15	-30
Operating Cash Flow to CapEx	-79.73%	984.50%	652.97%	-0.63%	75.75%	214.95%	52.06%	104.88%	-35.81%	653.19%	313.27%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-45.20
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	16.77
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	11.42
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.19	1.08	1.05	1.05	1.05	1.01	0.98	1.16	1.08	0.95	0.86
Accounts Receivable Turnover	10.19	8.78	9.37	9.86	10.01	8.27	9.51	10.13	9.89	8.55	9.27
Inventory Turnover	1.73	2.16	2.46	2.68	3.14	4.22	4.40	4.03	4.01	4.54	3.59
Fixed Asset Turnover	12.98	14.35	15.16	16.24	18.06	21.83	24.59	29.04	30.83	31.70	31.60
Accounts Payable Turnover	3.54	3.17	3.07	2.91	2.53	2.94	3.01	3.07	2.84	3.43	3.64
Days Sales Outstanding (DSO)	35.84	41.59	38.94	37.04	36.48	44.14	38.39	36.04	36.91	42.69	39.38
Days Inventory Outstanding (DIO)	210.47	169.17	148.39	136.17	116.28	86.49	83.05	90.52	90.92	80.37	101.71
Days Payable Outstanding (DPO)	103.24	115.04	118.90	125.46	144.42	124.13	121.44	118.72	128.47	106.31	100.30
Cash Conversion Cycle (CCC)	143.07	95.72	68.42	47.75	8.34	6.51	0.00	7.84	-0.65	16.76	40.79
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	222	173	172	172	120	103	77	62	53	45	43
Invested Capital Turnover	4.92	5.81	6.07	6.02	7.67	8.47	9.53	9.15	10.41	10.99	10.29
Increase / (Decrease) in Invested Capital	102	70	95	110	67	58	34	9.60	16	15	18
Enterprise Value (EV)	4,312	5,039	5,769	3,510	5,872	5,537	5,354	9,003	6,347	6,826	4,475
Market Capitalization	4,726	5,555	6,294	3,976	6,342	6,006	5,821	9,470	6,799	7,277	4,902
Book Value per Share	$21.43	$23.02	$23.36	$21.48	$19.89	$19.39	$18.55	$18.15	$17.37	$17.17	$17.01
Tangible Book Value per Share	$21.43	$23.02	$23.36	$21.48	$19.89	$19.39	$18.55	$18.15	$17.37	$17.17	$17.01
Total Capital	636	690	697	638	589	573	544	529	505	496	470
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-414	-517	-524	-466	-469	-470	-467	-467	-452	-451	-428
Capital Expenditures (CapEx)	8.41	7.03	8.01	12	12	8.03	6.99	4.86	3.75	2.95	3.51
Debt-free, Cash-free Net Working Capital (DFCFNWC)	139	97	97	102	59	55	35	26	22	17	19
Debt-free Net Working Capital (DFNWC)	508	542	508	542	500	516	500	493	474	469	446
Net Working Capital (NWC)	508	542	508	542	500	516	500	493	474	469	446
Net Nonoperating Expense (NNE)	-4.06	-4.57	-5.47	-5.19	-0.65	-5.76	-0.89	0.33	1.78	-3.47	4.81
Net Nonoperating Obligations (NNO)	-414	-517	-524	-466	-469	-470	-467	-467	-452	-451	-428
Total Depreciation and Amortization (D&A)	1.84	0.94	-0.56	-1.06	-1.63	-1.58	0.71	0.66	0.59	0.57	0.51
Debt-free, Cash-free Net Working Capital to Revenue	16.55%	12.05%	12.87%	14.43%	8.88%	8.84%	6.21%	5.01%	4.64%	4.27%	5.37%
Debt-free Net Working Capital to Revenue	60.49%	67.55%	67.27%	76.73%	75.66%	82.53%	87.62%	93.79%	101.57%	114.95%	128.10%
Net Working Capital to Revenue	60.49%	67.55%	67.27%	76.73%	75.66%	82.53%	87.62%	93.79%	101.57%	114.95%	128.10%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.10	$1.19	$0.62	$0.33	($0.34)	$0.51	($0.29)	($0.41)	($0.53)	$0.14	($0.60)
Adjusted Weighted Average Basic Shares Outstanding	29.70M	29.76M	29.88M	29.73M	29.62M	29.30M	29.37M	29.23M	29.09M	28.07M	28.23M
Adjusted Diluted Earnings per Share	$0.10	$1.17	$0.60	$0.32	($0.34)	$0.51	($0.29)	($0.41)	($0.53)	$0.14	($0.60)
Adjusted Weighted Average Diluted Shares Outstanding	30.31M	30.54M	30.63M	30.41M	29.62M	29.30M	29.37M	29.23M	29.09M	28.07M	28.23M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	29.49M	29.67M	29.97M	29.82M	29.71M	29.59M	29.52M	29.34M	29.17M	29.05M	28.89M
Normalized Net Operating Profit after Tax (NOPAT)	-1.07	31	13	4.60	-11	9.01	-9.43	-12	-14	-0.32	-12
Normalized NOPAT Margin	-0.53%	12.79%	6.41%	2.35%	-6.50%	4.68%	-6.15%	-7.69%	-10.67%	-0.23%	-11.02%
Pre Tax Income Margin	2.07%	15.28%	10.00%	5.54%	-5.70%	7.92%	-5.35%	-7.77%	-11.89%	2.37%	-15.20%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-26.36
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-18.35
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-31.72
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-23.70
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	225.56%	140.16%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Inspire Medical Systems' Financials

When does Inspire Medical Systems's financial year end?

According to the most recent income statement we have on file, Inspire Medical Systems' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Inspire Medical Systems' net income changed over the last 8 years?

Inspire Medical Systems' net income appears to be on a downward trend, with a most recent value of $53.51 million in 2024, falling from -$18.53 million in 2016. The previous period was -$21.15 million in 2023. Check out Inspire Medical Systems' forecast to explore projected trends and price targets.

What is Inspire Medical Systems's operating income?

Inspire Medical Systems's total operating income in 2024 was $36.08 million, based on the following breakdown:

Total Gross Profit: $679.82 million
Total Operating Expenses: $643.74 million

How has Inspire Medical Systems revenue changed over the last 8 years?

Over the last 8 years, Inspire Medical Systems' total revenue changed from $16.43 million in 2016 to $802.80 million in 2024, a change of 4,787.1%.

How much debt does Inspire Medical Systems have?

Inspire Medical Systems' total liabilities were at $118.69 million at the end of 2024, a 13.8% increase from 2023, and a 399.4% increase since 2017.

How much cash does Inspire Medical Systems have?

In the past 7 years, Inspire Medical Systems' cash and equivalents has ranged from $8.96 million in 2017 to $441.59 million in 2022, and is currently $150.15 million as of their latest financial filing in 2024.

How has Inspire Medical Systems' book value per share changed over the last 8 years?

Over the last 8 years, Inspire Medical Systems' book value per share changed from 0.00 in 2016 to 23.02 in 2024, a change of 2,301.5%.

Related Companies

This page (NYSE:INSP) was last updated on 5/25/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Inspire Medical Systems (INSP) Financials

Frequently Asked Questions About Inspire Medical Systems' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Inspire Medical Systems (INSP) Financials

Annual Income Statements for Inspire Medical Systems

Quarterly Income Statements for Inspire Medical Systems

Annual Cash Flow Statements for Inspire Medical Systems

Quarterly Cash Flow Statements for Inspire Medical Systems

Annual Balance Sheets for Inspire Medical Systems

Quarterly Balance Sheets for Inspire Medical Systems

Annual Metrics And Ratios for Inspire Medical Systems

Quarterly Metrics And Ratios for Inspire Medical Systems

Frequently Asked Questions About Inspire Medical Systems' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools